Altogether these findings indicate that downregulation of miR-21-5p expression by metformin, followed by release of CAB39L and SESN1, contributed to attenuating the mTOR aberrant activity and rendering breast cancer cells more prone to cell death induced by a clinically relevant mTOR inhibitor. This evidence concerns the gene MTOR and breast cancer.